Takeda reports pivotal data from FirstLight and RadiantLight trials
In both studies, oveporexton showed improvement at week 12 in daily functioning versus placebo across six FINI domains.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance